CSPC Pharmaceutical, AstraZeneca Form Joint Venture for New Biologics Manufacturing Facility in China

CSPC Pharmaceutical Group and AstraZeneca have entered into a contract to establish a joint venture for the construction of a new-generation biologics manufacturing facility in Shijiazhuang, China, deepening the companies' existing strategic collaboration. The announcement was disclosed in a voluntary filing by CSPC to the Hong Kong Stock Exchange on August 5, 2026.¹ Under the terms of the contract, CSPC and AstraZeneca will contribute capital at an equity ratio of 51% and 49%, respectively, and will jointly manage the construction and day-to-day operations of the joint venture.¹

What will the joint venture do?

The joint venture aims to combine CSPC's artificial intelligence-driven good manufacturing practice system and pharmaceutical manufacturing construction and operational capabilities with AstraZeneca's expertise in global quality standards and supply chain management. Its initial business scope will focus on the manufacturing and supply of mutually agreed biologics drug substances for global markets.¹

As the business develops, production capacity scales up, and commercial demand grows, the companies said they will explore incorporating additional products into the joint venture's scope of operations.¹ The joint venture contract remains subject to customary closing conditions, including necessary regulatory approvals.

What is the strategic rationale behind the deal?

CSPC described the collaboration as reflecting recognition of the company's modernized manufacturing system, quality management capabilities, and industrial-scale execution capabilities by a multinational pharmaceutical company.¹ The company characterized the joint venture as extending its internationalization path from exporting products and technologies to exporting manufacturing systems and supply chain capabilities.

CSPC said in the filing it believes the collaboration will strengthen its ability to meet manufacturing and supply demands in international markets and support additional innovative drug products entering those markets in the future.¹

How does this fit into AstraZeneca's broader activity in oncology and global expansion?

The manufacturing joint venture comes as AstraZeneca continues to expand its oncology portfolio through both regulatory approvals and partnerships. In late July 2026, the European Commission approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan), a TROP2-directed antibody-drug conjugate, as a first-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for programmed cell death protein 1/programmed cell death ligand 1 inhibitor therapy.² That approval was based on the phase 3 TROPION-Breast02 trial, in which Datroway showed a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival compared with chemotherapy. Reported results included a median overall survival of 23.7 months versus 18.7 months and a 43% reduction in the risk of disease progression or death.² The approval made Datroway the only TROP2-directed medicine with a demonstrated overall survival benefit in that setting and gave the drug a second approved breast cancer indication in the European Union.²

The Datroway approval and the CSPC manufacturing joint venture illustrate 2 distinct tracks of AstraZeneca's current growth strategy, which includes advancing its own oncology pipeline through clinical and regulatory milestones, while also building external manufacturing capacity and supply chain capabilities in China through partnerships with established local manufacturers.

What happens next?

The joint venture contract remains subject to closing conditions, including regulatory approvals, before construction of the Shijiazhuang facility can proceed. CSPC and AstraZeneca said that as the joint venture's business develops and commercial demand grows, they will consider expanding its scope to additional products beyond the initially agreed biologics drug substances.¹

References

1. CSPC Pharmaceutical Group Limited. Voluntary announcement: entering into a joint venture contract with AstraZeneca in relation to the establishment of a joint venture to further deepen strategic collaboration. Regulatory filing. Hong Kong Stock Exchange; August 5, 2026. Accessed August 6, 2026. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0805/2026080500460.pdf
2. AstraZeneca. Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy. Press release. Published July 31, 2026. Accessed August 6, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-approved-in-eu-for-tnbc.html